Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sunstar Inc. is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating that the company's active patent applications are being reviewed by different specialized groups. This spread suggests that the company's innovations in the biotech sector are diverse enough to fall under the jurisdiction of multiple examination units.
The busiest examiner for Sunstar Inc. is BRAM, STANLEY, who is responsible for 1 pending office action. Since the busiest examiner pending count of 1 is half of the total 2 pending office actions, the workload is evenly divided between the 2 distinct examiners. This distribution allows the company to engage with different examination styles, which can be beneficial for gathering varied feedback on their pharmaceutical and biological claims.
Practitioners should note that the presence of 2 distinct art units requires a versatile approach to prosecution, as each unit may have its own specific procedural nuances. With 2 pending office actions in play, the company must ensure consistent messaging across different examiners while addressing the unique concerns of each. This balanced distribution of matters helps to mitigate the risk of a single examiner's bottleneck affecting the entire active portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAM, STANLEY | 1 | 0.0% | +0.0% |
| PATEL, OM | 1 | 58.0% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843614 | COMPOSITION CONTAINING L-ASCORBIC ACID DL-a-TOCOPHEROL PHOSPHORIC ACID DIESTER ALKALI METAL SALT | BRAM, STANLEY | — |
| 17788636 | CHEWING ASSISTANCE SYSTEM | PATEL, OM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843614 | COMPOSITION CONTAINING L-ASCORBIC ACID DL-a-TOCOPHEROL PHOSPHORIC ACID DIESTER ALKALI METAL SALT | BRAM, STANLEY | 1691 | §102§103§112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 17788636 | CHEWING ASSISTANCE SYSTEM | PATEL, OM | 3791 | §101 | Final Rejection | — | Pending | Jun 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSunstar Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Stanley Bram has the most, with 1 of Sunstar Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
